Literature DB >> 11439749

Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation.

R Hammock1, W R Levine, S R Schroeder.   

Abstract

Atypical antipsychotic medications for self-injurious behavior (SIB), aggression, and destruction among people with mental retardation and development disabilities are becoming increasingly accepted. Most studies are on risperidone and fewer have been conducted on clozapine. The present single-blind study reports marked reductions in SIB and aggression of two persons with profound mental retardation who were nonresponsive to all other behavioral and psychopharmacological interventions, including risperidone. The most effective dose was 200 mg/day. Side effects were mild and the drug was tolerated well.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439749     DOI: 10.1023/a:1005626100084

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  10 in total

1.  Brief report: reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation.

Authors:  S R Schroeder; J Rojahn; R M Reese
Journal:  J Autism Dev Disord       Date:  1997-02

2.  The effect of clozapine on self-injurious behavior.

Authors:  R G Hammock; S R Schroeder; W R Levine
Journal:  J Autism Dev Disord       Date:  1995-12

3.  The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients.

Authors:  M Sajatovic; L F Ramirez; J T Kenny; H Y Meltzer
Journal:  Compr Psychiatry       Date:  1994 Jan-Feb       Impact factor: 3.735

4.  Use of clozapine in 10 mentally retarded adults.

Authors:  R D Buzan; S L Dubovsky; D Firestone; E Dal Pozzo
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1998       Impact factor: 2.198

5.  The use of clozapine in a mentally retarded and aggressive population.

Authors:  S A Cohen; M T Underwood
Journal:  J Clin Psychiatry       Date:  1994-10       Impact factor: 4.384

Review 6.  An overview of the mechanism of action of clozapine.

Authors:  H Y Meltzer
Journal:  J Clin Psychiatry       Date:  1994-09       Impact factor: 4.384

Review 7.  Clozapine therapy in patients with neurologic illness.

Authors:  M Sajatovic; L Ramirez
Journal:  Int J Psychiatry Med       Date:  1995       Impact factor: 1.210

8.  The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

Authors:  M G Aman; N N Singh; A W Stewart; C J Field
Journal:  Am J Ment Defic       Date:  1985-03

9.  Clozapine in three individuals with mild mental retardation and treatment-refractory psychiatric disorders.

Authors:  R J Pary
Journal:  Ment Retard       Date:  1994-10

10.  Study designs for dose-ranging.

Authors:  L B Sheiner; S L Beal; N C Sambol
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

  10 in total
  5 in total

Review 1.  Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.

Authors:  Noha F Minshawi; Sarah Hurwitz; Danielle Morriss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2015-06

2.  Clozapine for Treatment-Refractory Aggressive Behavior.

Authors:  Teodorescu Andreea; Ifteni Petru; Ana Aliana Miron; Petric Paula-Simina; Dima Lorena
Journal:  Psychiatr Q       Date:  2020-09-12

3.  Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases.

Authors:  Bastian Wollweber; Martin E Keck; Ulrike Schmidt
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

Review 4.  Diagnosis and treatment of aggression in individuals with developmental disabilities.

Authors:  Diana J Antonacci; Crystal Manuel; Ervin Davis
Journal:  Psychiatr Q       Date:  2008-08-23

Review 5.  Clozapine for psychotic disorders in adults with intellectual disabilities.

Authors:  Muhammad Ayub; Khalid Saeed; Tariq A Munshi; Farooq Naeem
Journal:  Cochrane Database Syst Rev       Date:  2015-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.